• Cytoprotective and supportive care agents

Zinecard Generic Name & Formulations

General Description

Dexrazoxane 250mg, 500mg; per vial; pwd for IV infusion after reconstitution and dilution.

Pharmacological Class

Chelating agent.

How Supplied

Single-use vial—1 (w. diluent)


Generic Availability


Zinecard Indications


To reduce the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300mg/m2 and will continue to receive doxorubicin therapy to maintain tumor control.

Zinecard Dosage and Administration


Give by slow IV push or rapid drip IV infusion. Doxorubicin should be administered within 30 minutes after starting Zinecard infusion. Administer in 10:1 ratio (eg, 500mg/m2 Zinecard: 50mg/m2 doxorubicin). Renal impairment (CrCl <40mL/min): reduce ratio to 5:1 (eg, 250mg/m2 Zinecard: 50mg/m2 doxorubicin). Hepatic impairment: may need to reduce doxorubicin dose, therefore Zinecard dose must be reduced (maintaining 10:1 ratio).


Not recommended.

Zinecard Contraindications


Chemotherapy regimens that do not contain an anthracycline.

Zinecard Boxed Warnings

Not Applicable

Zinecard Warnings/Precautions


Not recommended for use with initiation of doxorubicin. Renal or hepatic impairment. Monitor cardiac function and for myelosuppression; obtain CBCs frequently. Pregnancy (Cat.D); avoid. Nursing mothers: not recommended.

Zinecard Pharmacokinetics

See Literature

Zinecard Interactions

Not Applicable

Zinecard Adverse Reactions

Adverse Reactions

Inj site pain, myelosuppression, possible secondary malignancies (see literature).

Zinecard Clinical Trials

See Literature

Zinecard Note

Not Applicable

Zinecard Patient Counseling

See Literature